Telo Genomics Corp (TELO : TSX-V)
Common Stock
Follow TELO
TELO
Telo Genomics Corp
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-10.00%
1 Month
-35.71%
YTD
-10.00%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$4.52M
52W High
$0.10
52W Low
$0.03
P/E Ratio
-
50 Day MA
$0.05
200 Day MA
$0.05
Beta
0.04
Dividend Yield
-
Performance history
TELO returns since 2023
Telo Genomics Corp has traded since Nov 2023 in our data, with 0 up years out of 2 full calendar years. Its deepest fall was −85.4% (Nov 2023 to Sep 2026).
1 year / yr
−25.0%
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*−9.1%
- 2024−35.0%
- 2025−61.5%
- 2026*−10.0%
* Partial year (first year of data, or year to date).
$10,000 invested in TELO
- 1 year ago$7,500
- 2023 (start of our data)$2,045
- Best year
- 2024: −35.0%
- Worst year
- 2025: −61.5%
- All-time high in our data
- $0 on Nov 17, 2023 · now −81.3%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past TELO? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/4/2026 | $0.05 | $0.05 | $0.04 | $0.04 | $0.04 | 6,673 |
| 10/30/2026 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 7,722 |
| 10/29/2026 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,000 |
| 10/26/2026 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 5,000 |
| 10/23/2026 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 6,000 |
| 10/21/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 8,000 |
| 10/20/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 1,000 |
| 10/16/2026 | $0.07 | $0.07 | $0.06 | $0.06 | $0.06 | 101,022 |
| 10/13/2026 | $0.07 | $0.08 | $0.07 | $0.07 | $0.07 | 257,854 |
| 10/9/2026 | $0.06 | $0.07 | $0.06 | $0.07 | $0.07 | 185,463 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELO's historical volatility
30-Day Vol
214.5%
Annualized
90-Day Vol
163.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.04
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.04 | C$0.02 – C$0.09 |
| 60 trading days | C$0.04 | C$0.01 – C$0.11 |
| 90 trading days | C$0.04 | C$0.01 – C$0.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Free with a Wealth Awesome account
Keep analysing TELO, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.17M
- Profit Margin
- 0.00%
- ROE (TTM)
- -3055.75%
- EPS (Diluted)
- -0.03
- Book Value
- -0.02
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About TELO
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NTLX | NeuroThera Labs Inc. | $3.60 | +123.60% |
| CTH | CoTec Holdings Corp. | $0.98 | +30.67% |
| IMI | Ironman International Ltd. | $0.07 | +30.00% |
| GCV | Golden Star Capital Ventures Inc. | $0.26 | +20.93% |
| LXM | Lux Metals Corp. | $0.17 | +20.69% |
| BEA | Belmont Resources Inc | $0.09 | +20.00% |
| BLU | BluEnergies Ltd. | $4.50 | +20.00% |
| MTS | Metallis Resources Inc. | $0.10 | +18.75% |